General Information of Drug (ID: DMFNDUL)

Drug Name
BMS-984923 Drug Info
Synonyms
BMS-984923; UNII-3I1803DK5Z; 3I1803DK5Z; 1375752-78-5; CHEMBL4571075; BMS984923; (4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; SCHEMBL4541143; BDBM50536712; AKOS040756698; HY-122559; CS-0087012
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Cross-matching ID
PubChem CID
69084898
TTD Drug ID
DMFNDUL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AFQ056 DMMHSLC Fragile X syndrome LD55 Phase 2/3 [3]
ADX-48621 DM6GTMD Parkinson disease 8A00.0 Phase 2/3 [4]
RG-7090 DMX8JYN Fragile X syndrome LD55 Phase 2 [5]
STX-107 DMLNKX7 Autism spectrum disorder 6A02 Phase 2 [6]
ADX10059 DMGVKHQ Anxiety disorder 6B00-6B0Z Phase 2 [7]
McN3377 DMTCADJ Fragile X syndrome LD55 Phase 1/2 [8]
MK-3328 DMW2O5D Alzheimer disease 8A20 Phase 1 [9]
[3H]fenobam DMBOXA1 Allodynia MB40.1 Phase 1 [10]
RG7342 DMIW5NG Schizophrenia 6A20 Phase 1 [11]
Tetra-hydro-oxazolopyridine derivative 2 DMP65Z4 N. A. N. A. Patented [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 5 (mGluR5) TTHS256 GRM5_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT05804383) A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease. U.S.National Institutes of Health.
2 Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.
3 Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
4 Pipeline of Addex Pharma. Addex Pharma. 2009.
5 The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
6 Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
7 A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
8 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
10 Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
11 Clinical pipeline report, company report or official report of Roche.
12 mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.